| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Veraxa Biotech AG Ordinary Shares$1.76
-0.2 (-10.2%)
D 22Pipeline Score Richly Valued Biotech · Clinical
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
-
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
311.00 K
52 Week Range
-
% held by Insiders
75.93 %
% held by Institutions
41 %
Enterprise Value
-
Total Shares
141.29 M
Short %
0.46 %
Float Shares
51.85 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Veraxa Biotech AG Ordinary Shares
17Total events
2Upcoming
3Tier-1 (high impact)
2025 – 2028Coverage
Upcoming catalysts 2
TBD
T2IND Submission
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
▲Milestone PaymentCorporate
Subscribe to view catalyst details
TBD
▲Development Candidate NominationVXA-222Preclinical
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D22
Pipeline Score $4M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 21%
Micro Cap (rank 731 of 924)
Percentile RankVeraxa Biotech AG Ordinary Shares faces pipeline headwinds (22/100), with $81M risk-adjusted pipeline value, led by FLYSYN in Acute Myeloid Leukemia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FLYSYN Monoclonal antibody | Acute Myeloid Leukemia | Phase 1 | NCT02789254 | 9% | $81M | COMPLETED | 31 | - | - | Sep 27, 2021 | - | Dec 28, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRXA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VRXA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-VRXA
Jul 29, 2026VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
VERAXA Biotech AG has announced an update on its patent portfolio, filing new applications for its innovative T cell engager and antibody-drug-conjugate platforms. With over 50 patents granted in 14 countries, the company aims to protect its technologies through at least 2047. CEO Christoph Antz emphasized the importance of intellectual property in advancing their novel cancer therapies.
Read more →-VRXA
Jul 27, 2026▲ +11.7%on this newsshared move
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech AG has announced the advancement of its bispecific antibody drug conjugate program, VXA-222, following a key technical milestone in collaboration with OmniAb. The program aims to target two different antigens on solid tumors using a novel AND-gate logic. This partnership combines OmniAb's antibody discovery technologies with VERAXA's linker technology, paving the way for further development of promising cancer therapies.
Read more →-VRXA
Jul 24, 2026▲ +11.7%on this newsshared move
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
VERAXA Biotech AG held an Extraordinary General Meeting where shareholders approved all proposed resolutions with over 99.94% support. The approved amendments enhance the company's corporate and financing framework, allowing for strategic partnerships and growth initiatives. This reflects strong shareholder confidence in VERAXA's long-term strategy in developing innovative cancer therapeutics.
Read more →-VRXA
Jul 23, 2026▼ -9.3%on this newsshared move
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
VERAXA Biotech has appointed Christoph Erkel, Ph.D., as Chief Scientific Officer to lead the development of its BiTAC® technology platforms. Erkel, who has over 20 years of experience in antibody therapeutics, aims to enhance the company's pipeline and accelerate its clinical programs. He succeeds Rick Austin, who contributed significantly during his tenure.
Read more →-VRXA
Jul 20, 2026VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
VERAXA Biotech has received Scientific Advice from the Paul-Ehrlich-Institute regarding its BiTAC-TCE development plan. The feedback supports the biological rationale of the technology and provides clarity for future development. Initial data from the program indicates a promising safety profile and efficacy, suggesting a potential improvement over traditional therapies.
Read more →-VRXA
Jul 13, 2026VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
VERAXA Biotech has announced a collaboration with Ardigen to enhance its BiTAC pipeline using AI-driven drug discovery methods. This partnership aims to improve the selection of cancer target pairs for T cell engagers and antibody drug conjugates, potentially increasing success rates in drug development. The innovative approach may also widen the therapeutic window by minimizing toxicity.
Read more →-VRXA
Jul 10, 2026VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
VERAXA Biotech AG has appointed Carl von Halem as Interim Chief Financial Officer, succeeding Torsten Bürgermeister. Von Halem brings significant experience from his role at Xlife Sciences and is expected to aid in the company's expansion. VERAXA is also in the process of finalizing a permanent successor to support its growth strategy.
Read more →-VRXA
Jul 6, 2026▲ +7.4%on this news· ran to +49% by day 1
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech AG has reported significant advancements in its pipeline and partnering strategy, particularly with its BiTAC technology. The company aims to prioritize its BiTAC portfolio, with plans to have its first BiTAC-TCE candidate ready by early 2028. Recent industry events have generated positive feedback and interest in their therapeutic programs, enhancing their position for potential partnerships.
Read more →-VRXA
Jul 2, 2026▲ +18.3%on this news· ran to +60% by day 3shared move
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
VERAXA Biotech has begun cell line development for its BiTAC-TCE program in collaboration with ATUM, utilizing Leap-In Transposase technology. This initiative aims to create stable clonal cell lines essential for the clinical development of their T-cell engager candidates. The company highlights the importance of this step following encouraging preclinical results presented at the AACR Annual Meeting.
Read more →-VRXA
Jun 24, 2026▼ -21%on this news
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
VERAXA Biotech has expanded its R&D hub in Heidelberg, Germany, to support its growing drug development programs. This expansion allows for team growth and the installation of necessary laboratory equipment. The company focuses on innovative cancer therapies, particularly through its BiTAC strategy, which aims to improve treatment precision. The move reinforces its commitment to advancing its pipeline into clinical development.
Read more →-VRXA
Jun 18, 2026▼ -23.5%on this news· ran to -61% by day 3shared move
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
VERAXA Biotech has announced successful in vitro proof-of-concept data for its BiTAC-ADC technology platform, which aims to enhance precision in cancer treatment. The company will present this technology at the BIO International Convention, seeking partnerships to further develop its innovative cancer therapies. The platform is designed to minimize off-tumor toxicity while maximizing therapeutic effects.
Read more →-VRXA
Jun 18, 2026▼ -23.5%on this news· ran to -61% by day 3shared move
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel
VERAXA Biotech announced successful in vitro proof-of-concept for its new BiTAC-ADC technology platform, which aims to enhance the precision of cancer therapies. The company will showcase its findings and pursue partnership opportunities at the upcoming BIO International Convention in San Diego, California. The BiTAC platform promises to improve safety by reducing off-tumor toxicity commonly associated with traditional ADCs. Despite being early in development, the results indicate a viable therapeutic approach for selectively targeting cancer cells.
Read more →-VRXA
Jun 11, 2026Biotech to Debut as a Publicly Traded Company Pioneering
VERAXA Biotech AG has successfully completed its merger with Voyager Acquisition Corp and is scheduled to commence trading on the NASDAQ under the symbol VRXA on June 11, 2026. The company focuses on developing advanced cancer therapies using its proprietary BiTAC platform, which aims to improve treatment efficacy while minimizing side effects. Initial data from their BiTAC-TCE candidate suggests a promising safety and efficacy profile. The merger provides VERAXA with financial resources to progress their various cancer treatment programs into clinical stages.
Read more →-VRXA
Jun 10, 2026VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech AG has completed its business combination with Voyager Acquisition Corp., becoming a publicly traded company on the Nasdaq under the ticker VRXA. The merger enhances VERAXA's financial position with $27.5 million in secured notes and a $50 million share purchase agreement. The company is focused on developing next-generation cancer therapies using its proprietary BiTAC platform, which targets solid tumors with precision.
Read more →-VRXA
May 28, 2026VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech AG has announced a significant financial boost through a $27.5 million senior secured note and a $50 million share purchase agreement. These transactions are aimed at supporting the closing of its business combination with Voyager Acquisition Corp. and advancing its pipeline of next-generation cancer therapies. The company is also preparing for a NASDAQ listing, which is expected to enhance its market presence.
Read more →Competitive Position
How VRXA ranks across every disease it competes inCompetitive Position is a premium feature
See how VRXA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial